HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


House Cosmetics Bill Reintroduced; ICMAD Optimistic In New Political Climate

This article was originally published in The Rose Sheet

Executive Summary

With President-Elect Trump headed for the Oval Office and the GOP controlling both houses of Congress, the small-business trade group believes Republican Congressman Pete Sessions’ Safe Cosmetics Modernization Act could get a more earnest look this year. Reintroduced today, the bill proposes comprehensive federal preemption to ensure national uniformity in cosmetic regulations.

You may also be interested in...

Trade Groups Affirm Cosmetic Ingredient Review Support With View For Change

Personal Care Products Council and Independent Cosmetic Manufacturers and Distributors assert confidence in and support for Cosmetic Ingredient Review while also signaling an openness to alterations to the expert panel’s role as Congress considers changes to its purview. PCPC characterized recent WVE report’s claims as “baseless,” highlighting the expert panelists’ “world renowned” expertise as well as the panel’s open, public forums and peer-reviewed assessments.

PCPC Wants Cosmetics Reform Passed Before Threatened 'Blue Wave'

At the trade group's annual meeting in Palm Beach, Fla., leadership emphasized the importance of pushing cosmetics reform legislation over the finish line before November midterm elections. PCPC's support of a bipartisan proposal released by the Senate Health Committee largely hinges on preemption, the group indicated.

2017 In Review: FDA's Cosmetics Slowdown Could Bolster Case For Legislative Jumpstart

FDA's cosmetics activities fell off noticeably compared with 2016, and the change in the White House spurred the agency to begin looking for regulatory burdens to eliminate while shuffling priorities away from cosmetics to make do with proposed cuts in federal funding. In this climate, robust cosmetics oversight may depend on a legislative update, with multiple draft bills on the table.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts